CO6470857A2 - Lipopolisacárido de ochrobactrum intermedium y su uso como inmunoestimulante en mamiferos - Google Patents

Lipopolisacárido de ochrobactrum intermedium y su uso como inmunoestimulante en mamiferos

Info

Publication number
CO6470857A2
CO6470857A2 CO11166480A CO11166480A CO6470857A2 CO 6470857 A2 CO6470857 A2 CO 6470857A2 CO 11166480 A CO11166480 A CO 11166480A CO 11166480 A CO11166480 A CO 11166480A CO 6470857 A2 CO6470857 A2 CO 6470857A2
Authority
CO
Colombia
Prior art keywords
immunostimulant
lipopolisacárido
mammals
ochrobactrum intermedium
ochrobactrum
Prior art date
Application number
CO11166480A
Other languages
English (en)
Inventor
Escudero Manuel Fresno
Guisasola Juan Ignacio Ovejero
Original Assignee
Ovejero S A Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovejero S A Lab filed Critical Ovejero S A Lab
Publication of CO6470857A2 publication Critical patent/CO6470857A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al aislamiento, purificación y caracterización del lipopolisacárido (LPS) de la cepa Ochrobactrum Intermedium LMG3306, y su uso como inmunoestimulante de mamíferos, el procedimiento para la preparación de un compuesto farmacéutico para el tratamiento y)o la prevención de la sepsis y adyuvante para una vacuna en animales inmunodeprimidos y contra la Leishmaniosis.
CO11166480A 2009-06-04 2011-12-02 Lipopolisacárido de ochrobactrum intermedium y su uso como inmunoestimulante en mamiferos CO6470857A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200930265A ES2352780B2 (es) 2009-06-04 2009-06-04 Lipopolisacárido de ochrobactrum intermedium contra la sepsis.

Publications (1)

Publication Number Publication Date
CO6470857A2 true CO6470857A2 (es) 2012-06-29

Family

ID=41796455

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11166480A CO6470857A2 (es) 2009-06-04 2011-12-02 Lipopolisacárido de ochrobactrum intermedium y su uso como inmunoestimulante en mamiferos

Country Status (20)

Country Link
US (1) US9241954B2 (es)
EP (1) EP2437754B1 (es)
JP (1) JP5730862B2 (es)
KR (1) KR20120061045A (es)
CN (1) CN102802639A (es)
AU (1) AU2009347459A1 (es)
BR (1) BRPI0924393A2 (es)
CA (1) CA2763266A1 (es)
CL (1) CL2011003033A1 (es)
CO (1) CO6470857A2 (es)
CU (1) CU24041B1 (es)
EA (1) EA025766B1 (es)
ES (2) ES2352780B2 (es)
IL (1) IL216560A0 (es)
MX (1) MX2011012934A (es)
NZ (1) NZ596599A (es)
PL (1) PL2437754T3 (es)
SG (1) SG176660A1 (es)
WO (1) WO2010139352A1 (es)
ZA (1) ZA201200021B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103937722B (zh) * 2014-04-24 2016-10-26 烟台地元生物科技有限公司 中间苍白杆菌及微生物菌剂和它们的应用
CN106754562B (zh) * 2017-02-14 2020-06-02 南京中医药大学 一种高产细菌多糖的菌株及其发酵中药废弃物制备多糖的方法
CN106755186B (zh) * 2017-02-14 2020-03-31 南京中医药大学 一种中间苍白杆菌胞外多糖及其在土壤改良方面的应用
CN109182159B (zh) * 2018-07-27 2021-04-23 华南农业大学 一种n-酰基高丝氨酸内酯淬灭菌及其在病害防控中的应用
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CN111053789A (zh) * 2019-11-26 2020-04-24 湖南营养树生物科技有限公司 调节免疫系统的方法和组合物
RU2736933C1 (ru) * 2020-05-20 2020-11-23 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени Г.П. Сомова" (НИИ эпидемиологии и микробиологии имени Г.П. Сомова) Адъювант
CN111909874B (zh) * 2020-08-17 2022-08-19 东北农业大学 一株生防菌i-5及其在防治紫花苜蓿根腐病中的应用
CN112625943B (zh) * 2020-12-02 2021-11-16 安徽农业大学 一种玉米用溶钾菌剂及其制备方法和应用
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824310A (en) * 1991-10-22 1998-10-20 The United States Of America As Represented By The Department Of Health And Human Services Lipopplysaccharide conjugate vaccines
GB9706930D0 (en) 1997-04-04 1997-05-21 Univ Glasgow Leishmania vaccine
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2009012166A1 (en) * 2007-07-13 2009-01-22 Infectious Disease Research Institute Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis

Also Published As

Publication number Publication date
CN102802639A (zh) 2012-11-28
CU24041B1 (es) 2014-11-27
ES2352780A1 (es) 2011-02-23
CL2011003033A1 (es) 2012-07-06
ES2653202T3 (es) 2018-02-06
EP2437754B1 (en) 2017-09-20
CU20110223A7 (es) 2012-06-21
JP5730862B2 (ja) 2015-06-10
SG176660A1 (en) 2012-01-30
KR20120061045A (ko) 2012-06-12
MX2011012934A (es) 2012-04-30
ZA201200021B (en) 2013-03-27
EA025766B1 (ru) 2017-01-30
US9241954B2 (en) 2016-01-26
AU2009347459A1 (en) 2011-12-22
BRPI0924393A2 (pt) 2016-09-06
WO2010139352A1 (en) 2010-12-09
JP2012528805A (ja) 2012-11-15
US20120107352A1 (en) 2012-05-03
CA2763266A1 (en) 2010-12-09
NZ596599A (en) 2013-08-30
ES2352780B2 (es) 2011-09-15
IL216560A0 (en) 2012-02-29
EA201190309A1 (ru) 2012-05-30
PL2437754T3 (pl) 2018-03-30
EP2437754A1 (en) 2012-04-11

Similar Documents

Publication Publication Date Title
CO6470857A2 (es) Lipopolisacárido de ochrobactrum intermedium y su uso como inmunoestimulante en mamiferos
CL2014000630A1 (es) Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
CL2011002460A1 (es) Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple.
CR20120011A (es) Inhibidores de bace
AR062148A1 (es) Proceso quimico para la preparacion de intermediarios
CL2012002905A1 (es) Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo(e)azulenos sustituidos, moduladores del receptor de vasopresina v1a; procedimiento de preparacion; composición farmacéutica; y su uso para la prevención o el tratamiento de la dismenorrea, disfunción sexual masculina o femenina, ansiedad, entre otros.
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
CU20120137A7 (es) Hidrato del hidrocloruro de agomelatina y preparación de éste
RU2011134931A (ru) Штамм enterococcus, используемый для приготовления кисломолочных напитков
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
DK2133420T3 (da) Fremgangsmåde til fremstilling af L-aminosyrer under anvendelse af forbedrede stammer af familien Enterobacteriaceae
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
AR079341A1 (es) Octadepsipeptidos ciclicos a partir de cepas fungicas y su uso como antihelminticos o endoparasiticidas
CL2012002954A1 (es) Compuestos derivados de heterobiaril-ciclohexil-tetraazabenzo[e]azules sustituidos, modulares del receptor de vasopresina v1a; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o el tratamient5o de la dismenorrea, disfuncion sexual masculina o femenina, ansiedad, hipertension, entre otros.
CL2012002902A1 (es) Cepas de bacteriofagos especifica contra bacterias pertenecientes al genero vibrio para la profilaxis y terapia de vibrio anguillarum; y composicion antibacteriana que comprende dicha cepas.
CL2011002522A1 (es) Compuestos derivados de (piran-) o (tiopiran-)quinazolinadiona, inhibidores de fosfodiesterasa 7 (pde7); procedimiento de preparacion; composicicion farmaceutica; y uso para tratar una enfermedad inflamatoria, inmunoinflamatoria, cardiovascular, del sistema nervioso central y/o periferico.
CR20120627A (es) Procedimiento para la preparación de diácido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico cristalino y el uso para la preparación de primovist ®
BR112012030619A2 (pt) concentração de antígenos de vacina influenza sem liofilização.
UY34640A (es) Proceso para preparar cemento, morteros y composiciones, con tratamiento de ultrafinos, y composiciones, productos de cemento, y aplicaciones.
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
EA201270390A1 (ru) 1,2,4-триазин, который может быть использован в качестве ускорителя вулканизации, и способ его получения
JP2012250569A5 (es)
IN2015DN03944A (es)

Legal Events

Date Code Title Description
FG Application granted